An international pharmaceutical company must decide on the pricing and access strategy for the first targeted medicine approved in China to treat advanced non-small cell lung cancer, a high mortality condition, in ALK-positive patients. As the vast majority of patients in China would have to pay out of their own pocket, pricing the medicine at the international ex-factory price would make it unaffordable for many.
Pricing and access strategy for high-priced non-reimbursed new medicines:
- Medicine access barriers
- Affordability (ability-to-pay) analysis
- Inter-country and intra-(within)-country differential pricing
- Differential pricing
- Access to medicines
- Social responsibility